Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Update

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 149,700 shares, a growth of 6.0% from the November 30th total of 141,200 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 16,500 shares, the days-to-cover ratio is presently 9.1 days.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX opened at $3.17 on Thursday. Eupraxia Pharmaceuticals has a 52 week low of $2.20 and a 52 week high of $5.58. The stock has a market capitalization of $86.48 million and a price-to-earnings ratio of -4.40. The stock has a fifty day moving average of $3.13 and a 200-day moving average of $2.78.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. RODMAN&RENSHAW upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.